Open AccessCorrection of symptoms of impaired urination in men with the drug Diunorm®.
Author(s) -
С. В. Шкодкин,
A.V. Polischuk,
Sergei V. Chirkov,
О. В. Чурикова,
Н. А. Кравцова
Publication year - 2020
Publication title -
èksperimentalʹnaâ i kliničeskaâ urologiâ
Language(s) - English
Resource type - Journals
eISSN - 2712-8571
pISSN - 2222-8543
DOI - 10.29188/2222-8543-2020-13-4-76-80
Subject(s) - nocturia , medicine , tamsulosin , urination , lower urinary tract symptoms , urology , international prostate symptom score , urination disorder , urinary system , gynecology , prostate , cancer , hyperplasia
. Lower urinary tract symptoms are a socially significant problem on a global scale. Material and methods. The clinical study included 57 men with complaints of LUTS. Patients were randomized to receive LUTS medication. The main observation group consisted of 42 primary patients aged 41 to 67 years. For therapy in whom the drug Diunorm® was used at a dose of 400 mg once a day. The control group included 15 patients aged 50 to 64 years. As an initial therapy, Tamsulosin 0.4 mg was prescribed once a day. The observation period last 90 days in both groups. The effectiveness of therapy was assessed on the basis of questionnaire scales, ultrasound and uroflowmetry. Results and discussion. Conservative therapy of LUTS in both groups was accompanied by a subjective reduction in symptoms according to the total score on the IPSS scale (p 0.05). A significant increase in the maximum urination rate was recorded in patients taking Diunorm®. The growth rate was on average 29.3 ± 21.0% (p <0.001). Conclusion. The drug Diunorm® reliably and comparable to tamsulosin reduces the severity of LUTS and the frequency of nocturia in primary relatively young patients, without causing ejaculatory disorders.